ClinicalTrials.gg
CompletedNCT05569421Updated Aug 22, 2025Results posted

A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant

A Phase 1 interventional study of Treatment A: BGF MDI HFO and Treatment B: BGF MDI HFA in Chronic Obstructive Pulmonary Disease, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-22.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca — 14 open to participants now, 15 under way, 4 of them phase 3. Pulmonary Disease, Chronic Obstructive · AstraZeneca.

Enrollment
111th of 194
108 · median 137
Started
2022
with 9 others
Phase 1
42 of 284
none open now
Registered
243rd of 284
by date

Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 111th largest by enrollment of the 194 interventional ones that give a count, is one of 10 that started in 2022, is one of 42 in phase 1, and was the 243rd registered.

Pulmonary Disease, Chronic Obstructive

5,526 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

14 of the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, or all of them as a file.
02

Study summary

The study will evaluate bioequivalence, pharmacokinetics, safety, and tolerability of Budesonide, Glycopyrronium and Formoterol (BGF) metered dose inhaler (MDI) formulated with hydrofluoroolefin (HFO) [Test] and hydrofluoroalkane (HFA) [Reference] in healthy participants (male or female).

Read the detailed description

This is a Phase I, randomized, double-blind, single-dose, single-center, partial-replicate, 3 way cross-over study to assess pharmacokinetic and safety of BGF MDI when administered with different propellants, HFO (HFO-1234ze) - test and HFA (HFA-134a) - reference.

The study will comprise of:

  • A screening period up to 28 days prior to first dosing;
  • Three Treatment Periods: Participants will be resident at the Clinical Unit from the morning on the day before dosing with BGF MDI on Day -1 of Treatment Period 1, until 24 hours following the final dose on Day 2 of Treatment Period 3, with a washout period of 3 to 7 days between each dose; and
  • Follow-up: final safety Follow-up Phone Call within 3 to 7 days after the last administration of BGF MDI in Treatment Period 3.

Each participant will receive 3 single dose treatments of BGF MDI (Treatment A: BGF MDI HFO [Test]; Treatment B: BGF MDI HFA [Reference]) following an overnight fast of at least 8 hours on Day 1 of each treatment period.

The reference formulation will be administered during 2 of the 3 treatment periods.

There will be a minimum of a 3 to 7 day washout between administration of each treatment.

Each participant will be involved in the study for approximately 55 days.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • Bioequivalence
  • Propellant
  • Corticosteroid
  • Long acting muscarine agonist (LAMA)
  • Long acting beta agonist
  • Lung exposure
  • Healthy subjects
  • Inhaled corticosteroid (ICS)
  • Long-acting β2 agonist (LABA)
  • Next generation propellant (NGP)
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated, written prior to any study specific procedures.
  • Healthy male and female subjects aged 18 to 60 years with suitable veins for cannulation or repeated venepuncture.
  • Females must have a negative pregnancy test, must not be lactating
  • Have a (BMI) between 18 and 35 kg/m2 inclusive and weigh at least 50 kg and no more than 120 kg inclusive.
  • Subjects must have a ≥ 80% of the predicted normal value and an FEV1/FVC > 70% regarding age, height, and ethnicity.
  • Subjects must demonstrate proper inhalation technique and have the ability to properly use an MDI device after training.

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder which, in the opinion of the investigator, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate.
  • History or presence of gastrointestinal, hepatic, or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  • Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of medicinal product (IMP).
  • History of narrow angle glaucoma not adequately treated and/or change in vision that may be relevant.
  • History of symptomatic prostatic hypertrophy or bladder neck obstruction/urinary retention that, in the opinion of the investigator, is clinically significant.
  • Unresectable cancer that has not been in complete remission for at least 5 years.
  • Any clinically significant abnormalities in clinical chemistry, hematology, or urinalysis results at screening, as judged by the investigator.
  • Any clinically significant abnormalities on 12-lead (ECG)
  • Any positive result on screening for serum surface antigen, antibody, and (HIV) antibody.
  • Subject has a positive Reverse transcriptase- Polymerase chain reaction (RT-PCR) test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
  • Subject has clinical signs and symptoms consistent with SARS-CoV-2 infection, eg, fever, dry cough, dyspnea, sore throat, fatigue, or laboratory confirmed acute infection with SARS-CoV-2.
  • Subject who had severe course of Corona virus disease of 2019 (COVID-19) (extracorporeal membrane oxygenation, mechanically ventilated, Intensive Care Unit stay).
  • History of any respiratory disorders such as asthma, Chronic Obstructive Pulmonary Disorder (), or idiopathic pulmonary fibrosis.
  • Known or suspected history of alcohol or drug abuse.
  • Receipt of any investigational drug within 30 days or 5 half-lives (whichever is longer) prior to randomization.
  • Plasma donation within 1 month of screening or any blood donation/loss more than 500 mL during the 3 months prior to screening.
  • History of severe allergy/ or ongoing allergy/hypersensitivity.
  • Use of drugs with enzyme-inducing properties such as St John's Wort within 3 weeks prior to the first administration of IMP.
  • Current smokers or those who have smoked or used nicotine products (including e-cigarettes) within the 3 months prior to screening.
  • Use of any prescribed or non-prescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, megadose vitamins and minerals during the 2 weeks prior to the first administration of IMP.
  • Known or suspected history of alcohol or drug abuse or excessive intake of alcohol.
  • Excessive intake of caffeine-containing drinks or food. Excessive intake of caffeine defined as the regular consumption of more than 600 mg of caffeine per day or would likely be unable to refrain from the use of caffeine-containing beverages during confinement.
  • Subjects who have previously received BGF MDI HFO.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
108 participants (actual)

Study arms

  • Experimental
    Treatment A: BGF MDI HFO 160/7.2/4.8 μg ex-actuator

    Participants will receive Test formulation in 1 of 3 possible treatment sequences: ABB, BAB, or BBA. The reference formulation will be administered during 2 of the 3 treatment periods in order to estimate intra-subject variability.

    Drug: Treatment A: BGF MDI HFO · Drug: Treatment B: BGF MDI HFA

  • Experimental
    Treatment B: BGF MDI HFA 160/7.2/4.8 μg ex-actuator

    Participants will receive Reference formulation in 1 of 3 possible treatment sequences: ABB, BAB, or BBA. The reference formulation will be administered during 2 of the 3 treatment periods in order to estimate intra-subject variability.

    Drug: Treatment A: BGF MDI HFO · Drug: Treatment B: BGF MDI HFA

Interventions

  • DrugTreatment A: BGF MDI HFO

    Participants will receive 4 oral inhalations as a single dose - test formulation; administered during 1 treatment period.

    Also known as: Budesonide/Glycopyronium/Formoterol fumarate pressurized inhalation suspension, HFO

  • DrugTreatment B: BGF MDI HFA

    Participants will receive 4 oral inhalations as a single dose - reference formulation; administered during 2 treatment periods.

    Also known as: Budesonide/Glycopyronium/Formoterol fumarate pressurized inhalation suspension, HFA

06

What researchers measure

Primary outcomes

  1. Area Under Plasma Concentration-time Curve From Zero to Infinity (AUCinf)

    The AUCinf of budesonide, glycopryrronium and formoterol in participants was evaluated.

    Time frame: Day 1 and Day 2 of each treatment period (each treatment period is of 2 days)

  2. Area Under the Plasma Concentration-curve From Zero to the Last Quantifiable Concentration (AUClast)

    The AUClast of budesonide, glycopryrronium and formoterol in participants was evaluated.

    Time frame: Day 1 and Day 2 of each treatment period (each treatment period is of 2 days)

  3. Maximum Observed Plasma (Peak) Drug Concentration (Cmax)

    The Cmax of budesonide, glycopryrronium and formoterol in participants was evaluated.

    Time frame: Day 1 and Day 2 of each treatment period (each treatment period is of 2 days)

Secondary outcomes

  1. Time to Reach Peak or Maximum Observed Concentration or Response Following Drug Administration (Tmax)

    The tmax of budesonide, glycopryrronium and formoterol in participants was evaluated.

    Time frame: Day 1 and Day 2 of each treatment period (each treatment period is of 2 days)

  2. Terminal Rate Constant, Estimated by Log-linear Least Squares Regression of the Terminal Part of the Concentration-time Curve (λz)

    The λz of budesonide, glycopryrronium and formoterol in participants was evaluated.

    Time frame: Day 1 and Day 2 of each treatment period (each treatment period is of 2 days)

  3. Half-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve (t½λz)

    The t½λz of budesonide, glycopryrronium and formoterol in participants was evaluated.

    Time frame: Day 1 and Day 2 of each treatment period (each treatment period is of 2 days)

  4. Mean Residence Time of the Unchanged Drug in the Systemic Circulation From Zero to Infinity (MRTinf)

    The MRTinf of budesonide, glycopryrronium and formoterol in participants was evaluated.

    Time frame: Day 1 and Day 2 of each treatment period (each treatment period is of 2 days)

  5. Apparent Total Body Clearance of Drug From Plasma After Extravascular Administration (CL/F)

    The CL/F of budesonide, glycopryrronium and formoterol in participants was evaluated.

    Time frame: Day 1 and Day 2 of each treatment period (each treatment period is of 2 days)

  6. Volume of Distribution (Apparent) at Steady State Following Extravascular Administration (Based on Terminal Phase) (Vz/F)

    The Vz/F of budesonide, glycopryrronium and formoterol in participants was evaluated.

    Time frame: Day 1 and Day 2 of each treatment period (each treatment period is of 2 days)

  7. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    The safety and tolerability of single doses of BGF MDI HFO and BGF MDI HFA was evaluated in healthy participants.

    Time frame: From Screening up to Follow-up (3 to 7 days post final dose) [approximately 55 days]

07

Results

Posted Apr 29, 2025

Participant flow

This study was conducted in one study center in the US.

Participant flow — Overall Study
MilestoneTreatment Sequence ABBTreatment Sequence BABTreatment Sequence BBA
Started363636
Completed353636
Not completed100
Withdrew: Withdrawal by subject100

Outcome measures

PrimaryArea Under Plasma Concentration-time Curve From Zero to Infinity (AUCinf)

The AUCinf of budesonide, glycopryrronium and formoterol in participants was evaluated.

Time frame:
Day 1 and Day 2 of each treatment period (each treatment period is of 2 days)
Reported as:
Geometric mean · hour*picogram/milliliter (h*pg/mL)
Area Under Plasma Concentration-time Curve From Zero to Infinity (AUCinf)
hour*picogram/milliliter (h*pg/mL)Treatment ATreatment B (Replicate 1)Treatment B (Replicate 2)
Budesonide4047 ± 46.714112 ± 40.784012 ± 46.01
Glycopyronium85.62 ± 94.5581.10 ± 78.85120.9 ± 83.40
Formoterol124.3 ± 43.80121.3 ± 41.19125.0 ± 40.55
PrimaryArea Under the Plasma Concentration-curve From Zero to the Last Quantifiable Concentration (AUClast)

The AUClast of budesonide, glycopryrronium and formoterol in participants was evaluated.

Time frame:
Day 1 and Day 2 of each treatment period (each treatment period is of 2 days)
Reported as:
Geometric mean · h*pg/mL
Area Under the Plasma Concentration-curve From Zero to the Last Quantifiable Concentration (AUClast)
h*pg/mLTreatment ATreatment B (Replicate 1)Treatment B (Replicate 2)
Budesonide3943 ± 47.604003 ± 40.663905 ± 46.82
Glycopyrronium52.68 ± 52.6849.31 ± 84.3863.29 ± 72.90
Formoterol102.5 ± 48.47100.3 ± 45.89103.9 ± 42.47
PrimaryMaximum Observed Plasma (Peak) Drug Concentration (Cmax)

The Cmax of budesonide, glycopryrronium and formoterol in participants was evaluated.

Time frame:
Day 1 and Day 2 of each treatment period (each treatment period is of 2 days)
Reported as:
Geometric mean · picograms per milliliter (pg/mL)
Maximum Observed Plasma (Peak) Drug Concentration (Cmax)
picograms per milliliter (pg/mL)Treatment ATreatment B (Replicate 1)Treatment B (Replicate 2)
Budesonide1124 ± 65.671143 ± 60.791146 ± 65.91
Glycopyrronium17.09 ± 90.5220.41 ± 87.4619.70 ± 87.52
Formoterol23.48 ± 60.1224.54 ± 62.2226.12 ± 54.39
SecondaryTime to Reach Peak or Maximum Observed Concentration or Response Following Drug Administration (Tmax)

The tmax of budesonide, glycopryrronium and formoterol in participants was evaluated.

Time frame:
Day 1 and Day 2 of each treatment period (each treatment period is of 2 days)
Reported as:
Median · Hours
Time to Reach Peak or Maximum Observed Concentration or Response Following Drug Administration (Tmax)
HoursTreatment ATreatment B (Replicate 1)Treatment B (Replicate 2)
Budesonide0.35 (0.08 to 2.00)0.33 (0.08 to 2.02)0.33 (0.07 to 2.05)
Glycopyrronium0.03 (0.02 to 4.13)0.03 (0.03 to 2.02)0.03 (0.02 to 4.02)
Formoterol0.08 (0.03 to 4.02)0.08 (0.03 to 2.03)0.08 (0.03 to 2.12)
SecondaryTerminal Rate Constant, Estimated by Log-linear Least Squares Regression of the Terminal Part of the Concentration-time Curve (λz)

The λz of budesonide, glycopryrronium and formoterol in participants was evaluated.

Time frame:
Day 1 and Day 2 of each treatment period (each treatment period is of 2 days)
Reported as:
Geometric mean · 1/hour
Terminal Rate Constant, Estimated by Log-linear Least Squares Regression of the Terminal Part of the Concentration-time Curve (λz)
1/hourTreatment ATreatment B (Replicate 1)Treatment B (Replicate 2)
Budesonide0.1508 ± 25.190.1538 ± 25.240.1500 ± 24.99
Glycopyrronium0.05906 ± 97.130.06010 ± 92.160.03853 ± 100.5
Formoterol0.08911 ± 36.390.08926 ± 36.500.08625 ± 39.39
SecondaryHalf-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve (t½λz)

The t½λz of budesonide, glycopryrronium and formoterol in participants was evaluated.

Time frame:
Day 1 and Day 2 of each treatment period (each treatment period is of 2 days)
Reported as:
Geometric mean · Hours
Half-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve (t½λz)
HoursTreatment ATreatment B (Replicate 1)Treatment B (Replicate 2)
Budesonide4.596 ± 25.194.506 ± 25.244.622 ± 24.99
Glycopyrronium11.74 ± 97.1311.53 ± 92.1617.99 ± 100.5
Formoterol7.779 ± 36.397.766 ± 36.508.037 ± 39.39
SecondaryMean Residence Time of the Unchanged Drug in the Systemic Circulation From Zero to Infinity (MRTinf)

The MRTinf of budesonide, glycopryrronium and formoterol in participants was evaluated.

Time frame:
Day 1 and Day 2 of each treatment period (each treatment period is of 2 days)
Reported as:
Geometric mean · Hours
Mean Residence Time of the Unchanged Drug in the Systemic Circulation From Zero to Infinity (MRTinf)
HoursTreatment ATreatment B (Replicate 1)Treatment B (Replicate 2)
Budesonide4.855 ± 21.374.893 ± 24.304.924 ± 19.98
Glycopyrronium16.02 ± 93.6615.56 ± 86.1424.50 ± 96.84
Formoterol10.48 ± 29.2810.38 ± 30.4210.62 ± 33.34
SecondaryApparent Total Body Clearance of Drug From Plasma After Extravascular Administration (CL/F)

The CL/F of budesonide, glycopryrronium and formoterol in participants was evaluated.

Time frame:
Day 1 and Day 2 of each treatment period (each treatment period is of 2 days)
Reported as:
Geometric mean · Liters/hour (L/h)
Apparent Total Body Clearance of Drug From Plasma After Extravascular Administration (CL/F)
Liters/hour (L/h)Treatment ATreatment B (Replicate 1)Treatment B (Replicate 2)
Budesonide158.2 ± 46.71155.6 ± 40.78159.5 ± 46.01
Glycopyrronium336.4 ± 94.55355.1 ± 78.85238.2 ± 83.40
Formoterol154.5 ± 43.80158.2 ± 41.19153.6 ± 40.55
SecondaryVolume of Distribution (Apparent) at Steady State Following Extravascular Administration (Based on Terminal Phase) (Vz/F)

The Vz/F of budesonide, glycopryrronium and formoterol in participants was evaluated.

Time frame:
Day 1 and Day 2 of each treatment period (each treatment period is of 2 days)
Reported as:
Geometric mean · Liters (L)
Volume of Distribution (Apparent) at Steady State Following Extravascular Administration (Based on Terminal Phase) (Vz/F)
Liters (L)Treatment ATreatment B (Replicate 1)Treatment B (Replicate 2)
Budesonide1049 ± 47.841012 ± 39.181064 ± 45.06
Glycopyrronium5695 ± 43.165908 ± 46.446182 ± 44.59
Formoterol1734 ± 32.781773 ± 33.691782 ± 36.52
SecondaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

The safety and tolerability of single doses of BGF MDI HFO and BGF MDI HFA was evaluated in healthy participants.

Time frame:
From Screening up to Follow-up (3 to 7 days post final dose) [approximately 55 days]
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsTreatment ATreatment B (Replicate 1)Treatment B (Replicate 2)
Any AEs16219
Any SAE000
Any SAE with outcome of death000
Any AE leading to discontinuation of Investigational Product (IP)000
Any possibly related AE10124
Any possibly related SAE000

Adverse events

Collected over From Screening up to Follow-up Phone call (3 to 7 days post final dose) [approximately 55 days]. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A0/108 (0%)0/108 (0%)16/108 (14.8%)
Treatment B (Replicate 1)0/107 (0%)0/107 (0%)21/107 (19.6%)
Treatment B (Replicate 2)0/107 (0%)0/107 (0%)9/107 (8.4%)
Most frequent other events
Showing 10 of 39
Most frequent other events
EventTreatment ATreatment B (Replicate 1)Treatment B (Replicate 2)
HeadacheNervous system disorders4/1088/1071/107
ConstipationGastrointestinal disorders0/1082/1070/107
Back painMusculoskeletal and connective tissue disorders1/1082/1070/107
Catheter site painGeneral disorders0/1081/1072/107
Catheter site swellingGeneral disorders0/1080/1072/107
DizzinessNervous system disorders2/1081/1071/107
Catheter site bruiseGeneral disorders2/1081/1071/107
PharyngitisInfections and infestations0/1081/1070/107
Upper respiratory tract infectionInfections and infestations0/1080/1071/107
AnxietyPsychiatric disorders0/1081/1071/107

Baseline characteristics

The randomized analysis set consisted of all participants randomized into the study.

Age, Continuous
Age, Continuous(Years)Treatment Sequence ABBTreatment Sequence BABTreatment Sequence BBATotal
Mean36.0 ± 10.035.8 ± 9.639.5 ± 11.237.1 ± 10.3
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Sequence ABBTreatment Sequence BABTreatment Sequence BBATotal
Female14191649
Male22172059
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Treatment Sequence ABBTreatment Sequence BABTreatment Sequence BBATotal
White21192060
Black or African American881026
Asian4329
Other36413
08

Study locations

1 site
  • Research Site
    Glendale, California 91206, United States
09

References and documents

Publications

  • Bednarczyk A, Aurivillius M, Jassal M, Shah M, Raphiou I, Petullo D, Xu J, Heijer M, Sychowicz K, Collison K, Silva C, Reddy J, Han D, Goldwater R, Gillen M, Patel M. Bioequivalence of budesonide/glycopyrrolate/formoterol fumarate with a next-generation propellant versus hydrofluoroalkane-134a in healthy adults: phase I, randomized, double-blind, single-dose, partial-replicate, three-way cross-over lung exposure and total systemic exposure studies. Ther Adv Respir Dis. 2026 Jan-Dec;20:17534666261417149. doi: 10.1177/17534666261417149. Epub 2026 Feb 12. PubMed 41677208 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Apr 2023, 6 months.

Results were first posted in Apr 2025, 2 years after primary completion.

Of 158 industry-sponsored phase 1 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 9. This study's 6 months is above that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 2 and three quarters within 11.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2022
First posted
Oct 6, 2022
StartActual
Oct 11, 2022
Primary completionActual
Apr 14, 2023
CompletionActual
Apr 14, 2023
Results first posted
Apr 29, 2025
Last update
Aug 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05569421
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Oct 6, 2022
Start date
Oct 11, 2022
Primary completion
Apr 14, 2023
Completion
Apr 14, 2023
Results posted
Apr 29, 2025
Last update
Aug 22, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion